chemotherapy-induced

Fosaprepitant dimeglumine (MK-0517) 是 Aprepitant 的前药。它是一种神经激肽 1 受体拮抗剂，可用于预防化疗引起的恶心呕吐。

ACY-1083 是一种选择性和脑穿透性 HDAC6 抑制剂 (IC50：3 nM)，可有效逆转化疗引起的周围神经病变。

Phenothiazine (ENT 38) 是一种抗生素，具有杀虫，抗菌，驱虫和杀真菌活性。它也可研究神经系统疾病。

Palonosetron hydrochloride (RS 25259) 是一种 5-HT3 拮抗剂，用于预防和治疗化疗引起的恶心和呕吐。

Anethole trithione (Anetholtrithion) 是硫杂环胆碱，是一种胆汁分泌刺激剂，可增强唾液分泌并增加 mAChR 受体，用于口干症的研究。

Acetyl-L-carnitine hydrochloride (Acetyl L-carnitine hydrochloride) 是一种由内源性左旋肉碱的乙酰化形式的盐酸盐组成的营养补充剂，具有潜在的神经保护、认知增强、抗抑郁和免疫调节活性。还可缓解化疗、糖尿病或其他疾病引起的周围神经病变。此外，乙酰左旋肉碱可能通过增加T淋巴细胞成熟来调节免疫反应，并可能下调促炎细胞因子对病毒(如SARS-CoV-2)的反应。它还可能破坏ACE2信号通路并抑制活性氧(ROS)的产生。

EX-A5758是一种新型推定的小分子 nNOS-NOS1 AP 抑制剂，可抑制炎症性伤害感受和化疗引起的神经性疼痛，并与紫杉醇协同降低肿瘤细胞活力

(R,R)-Palonosetron Hydrochloride is the active enantiomer of Palonosetron

PF-477736, 亦称为PF-00477736，是一种有效的CHK1抑制剂，具有潜在的化疗增效活性。该化合物通过抑制chk1——一种ATP依赖的丝氨酸-苏氨酸激酶，该激酶是DNA复制监控的S G2检查点系统的关键组成部分。通过绕过对DNA损伤剂诱导的致命损伤的最后检查点防御，PF-477736可能增强对具有内在检查点缺陷的肿瘤细胞的各种化疗化合物的抗肿瘤效果。

Casopitant (GW679769) 是一种口服有效的神经激肽-1 (NK1) 受体拮抗剂，用于研究化疗引起的恶心和呕吐 (CINV) 以及术后恶心和呕吐 (PONV)。

Dolasetron Mesylate (MDL-73147EF) 是 5-HT3 受体的拮抗剂，可用于治疗化疗后呕吐和恶心的研究。

Palonosetron, a 5-HT3 antagonist with Ki of 0.17 nM, is used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).

Dolasetron Mesylate hydrate (Dalasetron Mesylate Hydrate) 是一种选择性血清素受体拮抗剂，可竞争性阻断血清素对 5HT3 受体的作用，从而抑制化疗和放疗引起的恶心和呕吐。

Alaproclate is a selective serotonin reuptake inhibitor (SSRI).1,2 It inhibits depletion of serotonin (5-HT) induced by 4-methyl-α-ethyl-m-tyramine in rat cerebral cortex, hippocampus, hypothalamus, and striatum (EC50s = 18, 4, 8, and 12 mg kg, respectively).1 Alaproclate inhibits NMDA-evoked currents and depolarization-induced voltage-dependent potassium currents in rat hippocampal neurons (IC50s = 1.1 and 6.9 μM, respectively) and does not inhibit GABA-evoked currents when used at concentrations up to 100 μM.2 It increases sirtuin 1 (SIRT1) levels in N2a murine neuroblastoma cells expressing apolipoprotein E4 (ApoE4; IC50 = 2.3 μM) and in the hippocampus in the FXFAD-ApoE4 transgenic mouse model of Alzheimer's disease when administered at a dose of 20 mg kg twice daily.3 Alaproclate (40 mg kg) decreases immobility time in the forced swim test in rats, indicating antidepressant-like activity.4References1. Michael, G.B., Eidam, C., Kadlec, K., et al. Increased MICs of gamithromycin and tildipirosin in the presence of the genes erm(42) and msr(E)-mph(E) for bovine Pasteurella multocida and Mannheimia haemolytica. Journal of Antimicrobial Chemotherapy 67(6), 1555-1557 (2012).2. Svensson, B.E., Werkman, T.R., and Rogawski, M.A. Alaproclate effects on voltage-dependent K+ channels and NMDA receptors: Studies in cultured rat hippocampal neurons and fibroblast cells transformed with Kv1.2 K+ channel cDNA. Neuropharmacology 33(6), 795-804 (1994).3. Campagna, J., Soilman, P., Jagodzinska, B., et al. A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer's disease mouse model. Sci. Rep. 8(1), 17574 (2018).4. Danysz, W.P., A., Kostowski, W., Malatynska, E., et al. Comparison of desipramine, amitriptyline, zimeldine and alaproclate in six animal models used to investigate antidepressant drugs. Pharmacol. Toxicol. 62(1), 42-50 (1988). Alaproclate is a selective serotonin reuptake inhibitor (SSRI).1,2 It inhibits depletion of serotonin (5-HT) induced by 4-methyl-α-ethyl-m-tyramine in rat cerebral cortex, hippocampus, hypothalamus, and striatum (EC50s = 18, 4, 8, and 12 mg kg, respectively).1 Alaproclate inhibits NMDA-evoked currents and depolarization-induced voltage-dependent potassium currents in rat hippocampal neurons (IC50s = 1.1 and 6.9 μM, respectively) and does not inhibit GABA-evoked currents when used at concentrations up to 100 μM.2 It increases sirtuin 1 (SIRT1) levels in N2a murine neuroblastoma cells expressing apolipoprotein E4 (ApoE4; IC50 = 2.3 μM) and in the hippocampus in the FXFAD-ApoE4 transgenic mouse model of Alzheimer's disease when administered at a dose of 20 mg kg twice daily.3 Alaproclate (40 mg kg) decreases immobility time in the forced swim test in rats, indicating antidepressant-like activity.4 References1. Michael, G.B., Eidam, C., Kadlec, K., et al. Increased MICs of gamithromycin and tildipirosin in the presence of the genes erm(42) and msr(E)-mph(E) for bovine Pasteurella multocida and Mannheimia haemolytica. Journal of Antimicrobial Chemotherapy 67(6), 1555-1557 (2012).2. Svensson, B.E., Werkman, T.R., and Rogawski, M.A. Alaproclate effects on voltage-dependent K+ channels and NMDA receptors: Studies in cultured rat hippocampal neurons and fibroblast cells transformed with Kv1.2 K+ channel cDNA. Neuropharmacology 33(6), 795-804 (1994).3. Campagna, J., Soilman, P., Jagodzinska, B., et al. A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer's disease mouse model. Sci. Rep. 8(1), 17574 (2018).4. Danysz, W.P., A., Kostowski, W., Malatynska, E., et al. Comparison of desipramine, amitriptyline, zimeldine and alaproclate in six animal models used to investigate antidepressant drugs. Pharmacol. Toxicol. 62(1), 42-50 (1988).

Rolapitant (SCH619734) 是一种高效选择性具有口服活性的神经激肽 1 受体抑制剂，Ki 值为0.66 nM。

(±)14(15)-EpETE是一种含有环氧基团的二十碳四烯酸衍生物，是肠道微生物脂质代谢物，通过靶向GCG PKA信号抑制Substance P释放减轻大鼠顺铂化疗诱导的恶心和呕吐，通常用于研究炎症和代谢。

Fabesetron (FK1052) is an orally active compound that acts as a dual antagonist, targeting both the 5-HT3 and 5-HT4 receptors. It exhibits efficacy in studying emesis induced by cancer chemotherapy, showing potential for managing both acute and delayed symptoms.

ZLc-002 是一种选择性的 nNOS-Capon 偶联小分子抑制剂。ZLc-002 抑制炎症和化疗引起的神经性疼痛。ZLc-002 可用于焦虑和炎症研究。

Sodium thiosulfate (Pentahydrate) is an antioxidant and antifungal. Sodium thiosulfate protects against cisplatin-induced hearing loss in children and is not associated with serious adverse events attributed to its use[3]. The addition of sodium thiosulfate, administered 6 hours after cisplatin chemotherapy, resulted in a lower incidence of cisplatin-induced hearing loss among children with standard-risk hepatoblastoma, without jeopardizing overall or event-free survival[4]. Calciphylaxis is a potentially fatal disorder of abnormal calcium deposition. Treatment is multifaceted, and improved outcomes have been demonstrated with intravenous sodium thiosulfate; however, the use of this medication can be limited by its adverse effects[5]. TST (topical sodium thiosulfate) appears to be a relatively well-tolerated adjuvant treatment for CC(calcinosis cutis)[6]. The combined treatment of sodium thiosulfate, pamidronate and calcitomimetics has been effective and safe for the treatment of calciphylaxis, inducing complete remission[7].

Rolapitant, also known as SCH-619734, is an orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor) antagonist with potential antiemetic activity. Upon oral administration, rolapitant competitively binds to and blocks the activity of the NK1-receptor in the central nervous system, thereby inhibiting the binding of the endogenous ligand, substance P (SP). This may prevent both SP-induced emesis and chemotherapy-induced nausea and vomiting (CINV). The interaction of SP with the NK1-receptor plays a key role in the induction of nausea and vomiting caused by emetogenic cancer chemotherapy.

Ac-Tyr-Val-Lys-Asp-aldehyde，一种caspase-1抑制剂，适用于慢性疾病相关贫血、化疗诱导贫血及钻石黑扇贫血的研究。

NAMPTactivator-3 是一种 NAT 衍生物，是一种 NAMPT 激活剂，EC50为 2.6 μM，KD 为 132 nM。NAMPTactivator-3 有效保护培养细胞免受 FK866 介导的毒性。NAMPTactivator-3 在化疗引起的周围神经病变 (CIPN) 小鼠模型中表现出强大的神经保护功效，没有任何明显的毒性。

(R)-Casopitant ((R)-GW679769) 是Casopitant 的异构体。Casopitant 是一种 NK(1)-受体拮抗剂。Casopitant 可用于化疗引起的恶心和呕吐的研究。

(Rac)-ZLc-002 是nNOS 与一氧化氮合酶 1 衔接蛋白 (NOS1AP) 相互作用的抑制剂，抑制炎症性痛觉和化疗诱导的神经性疼痛，并与 Paclitaxel 协同降低肿瘤细胞活力。